RCM-1
CAS No. 339163-65-4
RCM-1 ( —— )
Catalog No. M22465 CAS No. 339163-65-4
RCM-1 is an inhibitor of FOXM1. RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 74 | In Stock |
|
10MG | 127 | In Stock |
|
25MG | 267 | In Stock |
|
50MG | 442 | In Stock |
|
100MG | 644 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRCM-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionRCM-1 is an inhibitor of FOXM1. RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner.
-
DescriptionRCM-1 is an inhibitor of FOXM1. RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as the growth of cancer cell colonies in vitro. Treatment with RCM-1 increases the duration of mitosis and cell cycle in the cancer cell lines.RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces the growth of the human H2122 lung adenocarcinoma in mice. RCM-1 treatment reduces tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. RCM-1 treatment decreases the growth of Rd76-9 rhabdomyosarcomas in mice. The RCM-1-treated Rd76-9 tumors display reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces the growth of B16-FlO melanoma tumors in mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorFOXM1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339163-65-4
-
Formula Weight424.58
-
Molecular FormulaC20H12N2OS4
-
Purity>98% (HPLC)
-
SolubilityDMSO:16.67 mg/mL (39.26 mM; Need ultrasonic)
-
SMILESO=C(CSc1nc(cc(-c2cccs2)c1C#N)-c1cccs1)c1cccs1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. ARYL SULFONOHYDRAZIDES.WO2018057550A1.
molnova catalog
related products
-
Merepoxine
The herbs of Doronicum macrophyllum.
-
Epiaschantin
(+)-Epiaschantin shows marginal cancer cell line inhibitory activities. It also has anti-platelet aggregation activity.
-
Erythrosine
A tetraiodofluorescein used as a red coloring in some foods (cherries, fish), as a disclosure of DENTAL PLAQUE, and as a stain of some cell types. It has structural similarity to THYROXINE.